Neurologix's appointments are Inspired
This article was originally published in Scrip
Executive Summary
Neurologix, a biotech developing gene therapies for disorders of the brain and central nervous system, has appointed Adrian Adams and Andrew Koven, both former employees of Inspire Pharmaceuticals. Mr Adams takes the role of chairman and CEO, and Mr Koven joins as president and chief administrative officer. Mr Adams most recently served as president and CEO of Inspire, where he led the company through a strategic acquisition by Merck & Co for $430 million. Mr Koven was most recently Inspire's executive vice-president and chief administrative and legal officer.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.